Updated 2/23/26. The results chart includes audits where the findings have been finalized. Remaining audits are still under review. Information on Corrective Action Plans and Sanctions will be updated once approved by HRSA. HRSA recommends covered entities do not contact audited manufacturers regarding sanctions until a corrective action plan has been approved by HRSA and posted on this website.
Results posted for 2 audits.
| Manufacturer Sort descending | Labeler Codes Reviewed | State | OPA Findings | Sanction | Corrective Action Status |
|---|---|---|---|---|---|
| Neolpharma, Inc. | 55466 | PR |
Incorrect 340B OPAIS record – Incorrect entries in 340B OPAIS for Authorizing Official and Primary Contact information. Neolpharma did not offer covered outpatient drugs to eligible covered entities at the 340B ceiling price. Neolpharma did not submit quarterly pricing to 340B OPAIS pricing component. |
Repayment to covered entities |
Pending |
| Shield Therapeutics Inc | 73059 | MA |
No adverse findings |
None |
N/A Audit closure date: December 15, 2025 |